For several years, concern has been mounting about the privacy implications of using and disclosing prescription data. Several transactions forming part of a growing chain of valuable health information have come under scrutiny, including 1) the sale or transfer of prescription data from pharmacies to commercial data brokers;2) processing of the data to analyze physicians' prescribing patterns; 3)the subsequent sale of these prescribing patterns to pharmaceutical companies, among others, that use this information to customize their marketing strategies aimed at physicians. In part one of this two-part series, we discussed privacy concerns with respect to prescribers. In this second installment, we examine the privacy risks to patients from Canadian and US perspectives.
No takes yet. Share an insight, caveat, or question.
Emam et al. (2009) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: